News & Updates

Show Multimedia Only

Glucocorticoid-free control in a patient with relapsing EGPA within 6 months of treatment with an anti–IL-5

20 Feb 2026 by

A 75-year-old male nonsmoker was diagnosed with adult-onset asthma at 54 years old in 2004, with blood eosinophil counts (BEC) rising from 1,500 cells/ μL in 2004 to 1,800 cells/μL in 2006, while serum immunoglobulin E (IgE) remained normal. He tested negative for antineutrophil cytoplasmic antibody (ANCA) and stool ova/cysts.

Glucocorticoid-free control in a patient with relapsing EGPA within 6 months of treatment with an anti–IL-5

20 Feb 2026

Antibodies may predict ILD progression in SSc patients

18 Feb 2026 by

The presence of certain autoantibodies in patients with systemic sclerosis (SSc) is predictive of interstitial lung disease (ILD) progression, suggests a Singapore study.

Antibodies may predict ILD progression in SSc patients

18 Feb 2026

Shortened romosozumab course proves beneficial in postmenopausal osteoporosis

12 Feb 2026 by

Three months of romosozumab followed by 9 months of denosumab works just as well as 12 months of romosozumab for increasing bone mass in postmenopausal women at high risk of fracture, as shown in an open-label, noninferiority trial.

Shortened romosozumab course proves beneficial in postmenopausal osteoporosis

12 Feb 2026

New model identifies stages of salivary gland secretion function in Sjögren disease patients

10 Feb 2026 by

A novel ultrasonographic scoring model integrating precise definitions for each stage of salivary gland (SG) hypofunction addresses the clinical heterogeneity seen in patients with Sjögren disease (SjD) and demonstrates accuracy in reflecting three distinct stages of SG secretion function, reveals a study.

New model identifies stages of salivary gland secretion function in Sjögren disease patients

10 Feb 2026

CD19 CAR T cell therapy improves QOL, cuts healthcare costs in SLE

09 Feb 2026

Quality of life (QOL) among patients with systemic lupus erythematosus (SLE) improves following CD19 chimeric antigen receptor (CAR) T cell therapy, with also helps lessen the socioeconomic burden associated with active disease, a study has shown.

CD19 CAR T cell therapy improves QOL, cuts healthcare costs in SLE

09 Feb 2026

Treat-to-target ULT approach reduces cardiac risk in gout patients

04 Feb 2026 by

Treating gout patients with urate-lowering therapy (ULT) to meet a serum urate level below 6 mg/dL within 12 months results in a reduced risk of major adverse cardiovascular events, as shown in a new user cohort study.

Treat-to-target ULT approach reduces cardiac risk in gout patients

04 Feb 2026

Electrical stimulation shows promise in erosive hand osteoarthritis

01 Feb 2026

The use of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with erosive hand osteoarthritis is safe and well tolerated and may potentially relieve pain, particularly in those with greater synovial inflammation, according to the sham-controlled ESTIVAL trial.

Electrical stimulation shows promise in erosive hand osteoarthritis

01 Feb 2026

Original New Drug Application Approvals by US FDA (16-31 January 2026)

30 Jan 2026

New drug applications approved by US FDA as of 16-31 January 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 January 2026)

30 Jan 2026

Sublingual cyclobenzaprine fares well in fibromyalgia trial

27 Jan 2026 by

Taking sublingual cyclobenzaprine (TNX-102 SL) at bedtime relieves fibromyalgia symptoms and improves function, a phase III study suggests.

Sublingual cyclobenzaprine fares well in fibromyalgia trial

27 Jan 2026

Heart failure risk high in patients with systemic autoimmune inflammatory diseases

25 Jan 2026

Patients with systemic autoimmune inflammatory diseases—including systemic sclerosis, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA)—face an increased risk of heart failure (HF), as suggested in a retrospective study.

Heart failure risk high in patients with systemic autoimmune inflammatory diseases

25 Jan 2026

News & Updates

Showing Rheumatology articles

Showing

Specialty:

Glucocorticoid-free control in a patient with relapsing EGPA within 6 months of treatment with an anti–IL-5

Glucocorticoid-free control in a patient with relapsing EGPA within 6 months of treatment with an anti–IL-5

Antibodies may predict ILD progression in SSc patients

Antibodies may predict ILD progression in SSc patients

Shortened romosozumab course proves beneficial in postmenopausal osteoporosis

Shortened romosozumab course proves beneficial in postmenopausal osteoporosis

New model identifies stages of salivary gland secretion function in Sjögren disease patients

New model identifies stages of salivary gland secretion function in Sjögren disease patients

CD19 CAR T cell therapy improves QOL, cuts healthcare costs in SLE

CD19 CAR T cell therapy improves QOL, cuts healthcare costs in SLE

Treat-to-target ULT approach reduces cardiac risk in gout patients

Treat-to-target ULT approach reduces cardiac risk in gout patients

Electrical stimulation shows promise in erosive hand osteoarthritis

Electrical stimulation shows promise in erosive hand osteoarthritis

Original New Drug Application Approvals by US FDA (16-31 January 2026)

Original New Drug Application Approvals by US FDA (16-31 January 2026)

Sublingual cyclobenzaprine fares well in fibromyalgia trial

Sublingual cyclobenzaprine fares well in fibromyalgia trial

Heart failure risk high in patients with systemic autoimmune inflammatory diseases

Heart failure risk high in patients with systemic autoimmune inflammatory diseases